Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Clinical Trial ID NCT01519427

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	1.96
2	The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.	P T	2013	1.68
3	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	1.33
4	Beyond BRAF: where next for melanoma therapy?	Br J Cancer	2014	1.26
5	Pathways and therapeutic targets in melanoma.	Oncotarget	2014	1.17
6	Targeting the RAS oncogene.	Expert Opin Ther Targets	2013	1.02
7	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.	Onco Targets Ther	2015	0.99
8	New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy.	Clin Cancer Res	2012	0.93
9	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.	Front Oncol	2013	0.89
10	Combination therapies for the treatment of advanced melanoma: a review of current evidence.	Biochem Res Int	2014	0.86
11	Profile of selumetinib and its potential in the treatment of melanoma.	Onco Targets Ther	2014	0.81
12	Targeted Therapies in Melanoma: Translational Research at Its Finest.	J Invest Dermatol	2015	0.78
13	Combining targeted therapeutics in the era of precision medicine.	Br J Cancer	2015	0.75